BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder

NEXT STORY
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer
PREV STORY
Teleflex to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Drug Delivery Technologies Market worth US$3,425.52 Billion by 2031. Visiongain Research Inc.

author_avatar
NASDAQ Market News

Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology

COPENHAGEN, Denmark, May 07, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Helsinn appoints Eric Cornut and Lonnie Moulder to the Board of Directors

author_avatar
NASDAQ Market News